Centre Armand-Frappier Santé Biotechnologie, Institut National de la Recherche Scientifique, Laval, QC H7V 1B7, Canada.
Center for Integrative Infectious Disease Research (CIID), Department of Infectious Diseases, Molecular Virology, Heidelberg University, D-69120 Heidelberg, Germany.
Viruses. 2021 Oct 18;13(10):2092. doi: 10.3390/v13102092.
The dengue virus (DENV) causes the most prevalent arthropod-borne viral disease worldwide. While its incidence is increasing in many countries, there is no approved antiviral therapy currently available. In infected cells, the DENV induces extensive morphological alterations of the endoplasmic reticulum (ER) to generate viral replication organelles (vRO), which include convoluted membranes (CM) and vesicle packets (VP) hosting viral RNA replication. The viral non-structural protein NS4B localizes to vROs and is absolutely required for viral replication through poorly defined mechanisms, which might involve cellular protein partners. Previous interactomic studies identified the ATPase valosin-containing protein (VCP) as a DENV NS4B-interacting host factor in infected cells. Using both pharmacological and dominant-negative inhibition approaches, we show, in this study, that VCP ATPase activity is required for efficient DENV replication. VCP associates with NS4B when expressed in the absence of other viral proteins while in infected cells, both proteins colocalize within large DENV-induced cytoplasmic structures previously demonstrated to be CMs. Consistently, VCP inhibition dramatically reduces the abundance of DENV CMs in infected cells. Most importantly, using a recently reported replication-independent plasmid-based vRO induction system, we show that VP biogenesis is dependent on VCP ATPase activity. Overall, our data demonstrate that VCP ATPase activity is required for vRO morphogenesis and/or stability. Considering that VCP was shown to be required for the replication of other flaviviruses, our results argue that VCP is a pan-flaviviral host dependency factor. Given that new generation VCP-targeting drugs are currently evaluated in clinical trials for cancer treatment, VCP may constitute an attractive broad-spectrum antiviral target in drug repurposing approaches.
登革热病毒(DENV)引起了全球最普遍的虫媒病毒病。虽然在许多国家的发病率正在上升,但目前尚无批准的抗病毒疗法。在感染细胞中,DENV 会引起内质网(ER)的广泛形态改变,以产生病毒复制细胞器(vRO),其中包括卷曲膜(CM)和包含病毒 RNA 复制的囊泡包(VP)。病毒非结构蛋白 NS4B 定位于 vRO,并通过定义不明确的机制,可能涉及细胞蛋白伴侣,绝对需要病毒复制。先前的相互作用组学研究表明,ATP 酶包含缬氨酸蛋白(VCP)是感染细胞中 DENV NS4B 相互作用的宿主因子。在这项研究中,我们使用药理学和显性负抑制方法表明,VCP ATP 酶活性是 DENV 复制所必需的。当在没有其他病毒蛋白表达时,VCP 与 NS4B 相关联,而在感染细胞中,两种蛋白在先前证明为 CM 的大的 DENV 诱导的细胞质结构内共定位。一致地,VCP 抑制显著减少了感染细胞中 DENV CM 的丰度。最重要的是,使用最近报道的复制独立的基于质粒的 vRO 诱导系统,我们表明 VP 的生物发生依赖于 VCP ATP 酶活性。总的来说,我们的数据表明 VCP ATP 酶活性是 vRO 形态发生和/或稳定性所必需的。考虑到 VCP 被证明是其他黄病毒复制所必需的,我们的结果表明 VCP 是一种泛黄病毒宿主依赖性因子。鉴于新一代 VCP 靶向药物目前正在临床试验中用于癌症治疗,VCP 可能成为药物再利用方法中具有吸引力的广谱抗病毒靶标。